IL144831A0 - USE OF RECOMBINANT PARAINFLUENZA VIRUSES (PIVs) AS VECTORS TO PROTECT AGAINST INFECTION AND DISEASE CAUSED BY PIV AND OTHER HUMAN PATHOGENS - Google Patents

USE OF RECOMBINANT PARAINFLUENZA VIRUSES (PIVs) AS VECTORS TO PROTECT AGAINST INFECTION AND DISEASE CAUSED BY PIV AND OTHER HUMAN PATHOGENS

Info

Publication number
IL144831A0
IL144831A0 IL14483100A IL14483100A IL144831A0 IL 144831 A0 IL144831 A0 IL 144831A0 IL 14483100 A IL14483100 A IL 14483100A IL 14483100 A IL14483100 A IL 14483100A IL 144831 A0 IL144831 A0 IL 144831A0
Authority
IL
Israel
Prior art keywords
pivs
piv
vectors
protect against
disease caused
Prior art date
Application number
IL14483100A
Original Assignee
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/458,813 external-priority patent/US7314631B1/en
Priority claimed from US09/459,062 external-priority patent/US7250171B1/en
Application filed by Us Health filed Critical Us Health
Publication of IL144831A0 publication Critical patent/IL144831A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18611—Respirovirus, e.g. Bovine, human parainfluenza 1,3
    • C12N2760/18622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18611—Respirovirus, e.g. Bovine, human parainfluenza 1,3
    • C12N2760/18641—Use of virus, viral particle or viral elements as a vector
    • C12N2760/18643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL14483100A 1999-12-10 2000-12-08 USE OF RECOMBINANT PARAINFLUENZA VIRUSES (PIVs) AS VECTORS TO PROTECT AGAINST INFECTION AND DISEASE CAUSED BY PIV AND OTHER HUMAN PATHOGENS IL144831A0 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US17019599P 1999-12-10 1999-12-10
US09/458,813 US7314631B1 (en) 1997-05-23 1999-12-10 Use of recombinant live-attenuated parainfluenza virus (PIV) as a vector to protect against disease caused by PIV and respiratory syncytial virus (RSV)
US09/459,062 US7250171B1 (en) 1997-05-23 1999-12-10 Construction and use of recombinant parainfluenza viruses expressing a chimeric glycoprotein
PCT/US2000/033293 WO2001042445A2 (en) 1999-12-10 2000-12-08 USE OF RECOMBINANT PARAINFLUENZA VIRUSES (PIVs) AS VECTORS TO PROTECT AGAINST INFECTION AND DISEASE CAUSED BY PIV AND OTHER HUMAN PATHOGENS

Publications (1)

Publication Number Publication Date
IL144831A0 true IL144831A0 (en) 2002-06-30

Family

ID=27389780

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14483100A IL144831A0 (en) 1999-12-10 2000-12-08 USE OF RECOMBINANT PARAINFLUENZA VIRUSES (PIVs) AS VECTORS TO PROTECT AGAINST INFECTION AND DISEASE CAUSED BY PIV AND OTHER HUMAN PATHOGENS

Country Status (8)

Country Link
EP (1) EP1179054A2 (en)
JP (1) JP4795597B2 (en)
CN (2) CN1347453A (en)
AU (1) AU785148B2 (en)
CA (1) CA2362685A1 (en)
IL (1) IL144831A0 (en)
MX (1) MXPA01008108A (en)
WO (1) WO2001042445A2 (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6764685B1 (en) 2000-03-21 2004-07-20 Medimmune Vaccines, Inc. Recombinant parainfluenza virus expression systems and vaccines
US8715922B2 (en) 2001-01-19 2014-05-06 ViroNovative Virus causing respiratory tract illness in susceptible mammals
CA2435180C (en) 2001-01-19 2019-04-09 Vironovative B.V. A virus causing respiratory tract illness in susceptible mammals
EP2100955A3 (en) 2001-11-21 2009-12-02 The United States of America, represented by The Secretary, Dept. of Health and Human Services Attenuated mutants of human parainfluenza virus type 1 (HPIV1)
CA2477234C (en) 2002-02-21 2014-12-30 Medimmune Vaccines, Inc. Metapneumovirus strains and their use in vaccine formulations and as vectors for expression of antigenic sequences
WO2004003511A2 (en) 2002-07-01 2004-01-08 Wayne State University Methods and compositions for the identification of antibiotics that are not susceptible to antibiotic resistance
US7820181B2 (en) 2002-09-18 2010-10-26 The United States Of America As Represented By The Department Of Health And Human Services Recovery of recombinant human parainfluenza virus type 2 (HPIV2) from cDNA and use of recombinant HPIV2 in immunogenic compositions and as vectors to elicit immune responses against PIV and other human pathogens
US7704491B2 (en) 2003-02-28 2010-04-27 The United States Of America As Represented By The Department Of Health And Human Services Recombinant human metapneumovirus and its use
CA2523319A1 (en) 2003-04-25 2004-11-11 Medimmune Vaccines, Inc. Metapneumovirus strains and their use in vaccine formulations and as vectors for expression of antigenic sequences and methods for propagating virus
BRPI0411247A (en) 2003-06-09 2006-07-25 Wyeth Corp improved process for recovering non-segmented negative filament rna viruses from cdna
DE102005006388A1 (en) 2005-02-11 2006-08-24 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Replication-deficient RNA viruses as vaccines
WO2006122277A2 (en) * 2005-05-11 2006-11-16 Wayne State University Novel targets for the identification of antibiotics that are not susceptible to antibiotic resistance
US8293517B2 (en) 2005-05-11 2012-10-23 Wayne State University Methods and compositions for the identification of antibiotics that are not susceptible to antibiotic resistance in Pseudomonas aeruginosa
JP4905649B2 (en) * 2006-03-08 2012-03-28 国立大学法人 長崎大学 Fish vaccine, method for producing the same, and method for preventing fish infection
JP4892296B2 (en) * 2006-08-24 2012-03-07 川崎製薬株式会社 Vaccines for fish edovagerosis and streptococcal disease
US8362203B2 (en) 2009-02-10 2013-01-29 Wayne State University Non-natural peptides as models for the development of antibiotics
CN108130345A (en) 2012-01-24 2018-06-08 乔治亚大学研究基金公司 Vaccine based on parainfluenza virus 5
CN103773803A (en) * 2014-01-23 2014-05-07 中国农业科学院特产研究所 Recombined cattle parainfluenza carrier for expressing protein VP1 of porcine O type foot-and-mouth disease virus
EP3630173A1 (en) * 2017-05-29 2020-04-08 The United States of America, as represented by the Secretary, Department of Health and Human Services Recombinant chimeric bovine/human parainfluenza virus 3 expressing rsv g and its use
CA3103842A1 (en) * 2018-06-27 2020-01-02 Medicago Inc. Influenza virus hemagglutinin mutants
EP3844758A1 (en) * 2018-08-28 2021-07-07 Koninklijke Philips N.V. Method for assessing genome alignment basis
CN113462656B (en) * 2021-03-24 2022-09-30 兰州生物制品研究所有限责任公司 Human three-type parainfluenza virus cold-adaptation temperature-sensitive strain and application thereof
CN113999292B (en) * 2021-10-27 2023-05-26 中国农业大学 Polypeptide inhibitors targeting respiratory viruses
WO2023227758A1 (en) 2022-05-25 2023-11-30 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Vaccine with reduced anti-vector antigenicity

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2291216A1 (en) * 1997-05-23 1998-11-26 Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services National Institutes Of Health Production of attenuated parainfluenza virus vaccines from cloned nucleotide sequences
KR100940776B1 (en) * 1999-07-09 2010-02-11 더 가버먼트 오브 더 유나이티드 스테이츠 오브 어메리카 애즈 리프리젠티드 바이 더 디파트먼트 오브 헬스 앤 휴먼 서비씨즈 Attenuated Human-Bovine Chimeric Parainfluenza Virus PIV Vaccines

Also Published As

Publication number Publication date
AU2073101A (en) 2001-06-18
WO2001042445A3 (en) 2001-11-29
EP1179054A2 (en) 2002-02-13
CA2362685A1 (en) 2001-06-14
AU785148B2 (en) 2006-10-05
CN102766605A (en) 2012-11-07
JP2003516148A (en) 2003-05-13
CN1347453A (en) 2002-05-01
MXPA01008108A (en) 2004-11-12
JP4795597B2 (en) 2011-10-19
WO2001042445A2 (en) 2001-06-14

Similar Documents

Publication Publication Date Title
IL144831A0 (en) USE OF RECOMBINANT PARAINFLUENZA VIRUSES (PIVs) AS VECTORS TO PROTECT AGAINST INFECTION AND DISEASE CAUSED BY PIV AND OTHER HUMAN PATHOGENS
ATE296040T1 (en) AIR-PERMEABLE CLOTHING TO IMPROVE THE COMFORT OF THE HUMAN BODY
CA2293470A1 (en) Benzimidazole derivatives
AU2001281309A1 (en) The use of c3-c5 monosaccharides to protect keratinous fibers
GR1002767B (en) Insecticidal composition for treating and protecting domestic an
BR9710740A (en) Polynucleotide vaccine formula against respiratory and reproductive diseases of pigs
AU3947301A (en) The use of plant extracts and sugars to protect keratinous tissue
ATE328889T1 (en) L-NUCLEOSIDES FOR THE TREATMENT OF HEPATITIS B AND EPSTEIN BAR VIRUS
NO983083D0 (en) Medical device to improve skin fixation of permanent catheters and other transcutaneous implants at reduced infection risk
HK1074221A1 (en) Genotyping kit for diagnosis of human papilloma virus infection
HK1060847A1 (en) Recombinant raccoon pox viruses and their use as an effective vaccine against feline immunodeficiency virus infection
IS5191A (en) Antimicrobial barrier and treatment of the erosion virus and other human infectious diseases
ID27867A (en) OBJECTS OF ABSORPTION MAY BE DISPOSED TO THE BODY TO HAVE AN ADDITIONAL CUTTING ACCORDING TO THE BODY ANATOMY
AU2002219881A1 (en) Methods and compositions for the treatment of human immunodeficiency virus infection
PL364171A1 (en) Crystals of an oxyiminoalkanoic acid derivative and their use as antidiabetics
DE10084499T1 (en) Absorbent tissue to improve the skin's protective layer
EE200300502A (en) Use of cationic dextran derivatives to protect dose limiting organs
ATE223725T1 (en) HERBAL ANTIVIRAL AGENT
HUP0101410A2 (en) Elastic member and disposable garment having improved fitness to body during entire use
ITMI913493A1 (en) DEVICE FOR DISINFECTION OR IMMUNIZATION OF AREAS OF THE HUMAN BODY EXPOSED TO INFECTION, FROM GERMS, BACTERIA AND VIRUSES
NO970185D0 (en) Use of (S) -adenosyl-L-methionine (SAMe) and its physiologically compatible salts for the treatment of reperfusion injury triggered by temporal-focal ischemia
NO20022393L (en) Treatment of cardiac arrhythmias with N6-substituted-5'- (N-substituted) -carboxamidoadenosines
IL151033A0 (en) Purified hepatitis c virus envelope proteins for diagnostic and therapeutic use
ID28053A (en) ENZYMATIC ACID NUCLEATIC TREATMENT IN DISEASES OR CONDITIONS RELATING TO HEPATITIC VIRUS INFECTION C
IT1270810B (en) DEVICE FOR THE PROTECTION OF THE HUMAN BODY FROM THE INFLUENCE OF EXTERNAL ELECTROMAGNETIC FIELDS